In a report released today, Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report), with a price target of $18.00. The company’s ...

Bank of New York Mellon Corp raised its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 2.8% during the fourth quarter, HoldingsChannel.com reports.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: 17 March at 7:50:24 pm GMT-4 Loading Chart for IOVA ...